• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌中的神经内分泌分化。一项回顾性尸检研究。

Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.

作者信息

Turbat-Herrera E A, Herrera G A, Gore I, Lott R L, Grizzle W E, Bonnin J M

机构信息

Department of Pathology, University of Alabama.

出版信息

Arch Pathol Lab Med. 1988 Nov;112(11):1100-5.

PMID:2460064
Abstract

Neuroendocrine differentiation in prostatic neoplasms has in the past been considered extremely uncommon. The histologic neuroendocrine patterns reported previously vary from small cell to carcinoidlike to mixed adenocarcinoma--small cell or carcinoid. The majority of the tumors reported are of the mixed variety. We reviewed 2648 autopsies, revealing 69 prostatic carcinomas, eight with neuroendocrine differentiation (five mixed adenocarcinoma--small-cell carcinoma, two "pure" small cell, and one "pure" carcinoidlike). The mean patient age was 69.5 years. One patient presented with markedly elevated serum corticotropin and another was severely hypercalcemic with elevated serum parathyroid hormone level. Three neoplasms were incidental autopsy findings. The mean survival time, after diagnosis, was 19 months for the other patients. Three of the cases were examined ultrastructurally and showed cytoplasmic processes containing membrane-bound granules in the neuroendocrine component. The areas with neuroendocrine differentiation were positive for markers as follows: neuron-specific enolase, seven of eight; prostate-specific antigen (PSA), none of eight; chromogranin A, seven of eight; synaptophysin, four of eight; and calcitonin, four of eight. Those neoplasms mixed with an adenocarcinoma component showed well-defined PSA positivity in the glandular elements. This study suggests that neuroendocrine differentiation in prostatic neoplasms may be more common than previously thought. Often, the areas with neuroendocrine differentiation are considered to represent poorly differentiated adenocarcinoma. It is important to recognize neuroendocrine components in prostatic carcinomas owing to prognostic and potential therapeutic implications.

摘要

前列腺肿瘤中的神经内分泌分化在过去一直被认为极为罕见。先前报道的组织学神经内分泌模式从小细胞型到类癌样再到混合性腺癌——小细胞或类癌不等。报道的大多数肿瘤为混合型。我们回顾了2648例尸检,发现69例前列腺癌,其中8例有神经内分泌分化(5例混合性腺癌——小细胞癌,2例“纯”小细胞癌,1例“纯”类癌样)。患者平均年龄为69.5岁。1例患者血清促肾上腺皮质激素显著升高,另1例严重高钙血症且血清甲状旁腺激素水平升高。3例肿瘤为尸检偶然发现。其他患者诊断后的平均生存时间为19个月。对其中3例进行了超微结构检查,神经内分泌成分显示含有膜结合颗粒的细胞质突起。神经内分泌分化区域对以下标志物呈阳性:神经元特异性烯醇化酶,8例中有7例;前列腺特异性抗原(PSA),8例中无1例;嗜铬粒蛋白A,8例中有7例;突触素,8例中有4例;降钙素,8例中有4例。那些与腺癌成分混合的肿瘤在腺性成分中显示出明确的PSA阳性。这项研究表明,前列腺肿瘤中的神经内分泌分化可能比以前认为的更为常见。通常,神经内分泌分化区域被认为代表低分化腺癌。认识前列腺癌中的神经内分泌成分很重要,因为其具有预后和潜在的治疗意义。

相似文献

1
Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.前列腺癌中的神经内分泌分化。一项回顾性尸检研究。
Arch Pathol Lab Med. 1988 Nov;112(11):1100-5.
2
Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.人前列腺肿瘤中神经内分泌分化的评估及临床价值
Prostate Suppl. 1998;8:43-51.
3
[Prostatic adenocarcinoma with neuroendocrine differentiation of the small cell type].[伴有小细胞型神经内分泌分化的前列腺腺癌]
Medicina (B Aires). 2001;61(3):322-4.
4
Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma.微管相关蛋白-2:一种用于肺类癌和小细胞癌的新型敏感且特异的标志物。
Mod Pathol. 2001 Sep;14(9):880-5. doi: 10.1038/modpathol.3880406.
5
A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines.肺癌细胞系中突触素、嗜铬粒蛋白和L-多巴脱羧酶作为神经内分泌分化标志物的比较
Cancer Res. 1990 Sep 15;50(18):6068-74.
6
The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.神经内分泌标志物和癌胚抗原在I期和II期非小细胞肺癌切除患者中的预后意义
Cancer Res. 1994 Jun 1;54(11):2908-13.
7
Serum calcitonin in small cell carcinoma of the prostate.前列腺小细胞癌中的血清降钙素
Ann Clin Lab Sci. 1996 Nov-Dec;26(6):487-95.
8
Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.偶发性前列腺腺癌中神经内分泌染色及雄激素受体表达的评估:预后意义
Urology. 2005 Oct;66(4):897-902. doi: 10.1016/j.urology.2005.04.064.
9
Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.良性前列腺增生症和前列腺癌患者的血浆神经内分泌标志物
J Urol. 1996 Apr;155(4):1340-3.
10
Immunohistochemical identification of neuron-specific enolase, synaptophysin, chromogranin and endocrine granule constituent in neuroendocrine tumours.神经内分泌肿瘤中神经元特异性烯醇化酶、突触素、嗜铬粒蛋白及内分泌颗粒成分的免疫组化鉴定
Acta Histochem Suppl. 1990;38:179-81.

引用本文的文献

1
Clinical and Genomic Features of Androgen Indifferent Prostate Cancer.雄激素不敏感型前列腺癌的临床和基因组特征
Int J Mol Sci. 2025 Jan 15;26(2):679. doi: 10.3390/ijms26020679.
2
Prognostic Nomogram Predicting Survival and Propensity Score Matching with Demographics and Comparative Analysis of Prostate Small Cell and Large Cell Neuroendocrine Carcinoma.预测生存的预后列线图、人口统计学倾向评分匹配以及前列腺小细胞和大细胞神经内分泌癌的比较分析
J Clin Med. 2024 Aug 18;13(16):4874. doi: 10.3390/jcm13164874.
3
Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature.
转移性去势抵抗性前列腺癌中的异位库欣综合征:一例报告并文献复习
Oncol Lett. 2024 Jul 1;28(3):417. doi: 10.3892/ol.2024.14550. eCollection 2024 Sep.
4
Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.《“现代时代”治疗的尿路上皮神经内分泌肿瘤:多中心回顾性研究》。
Clin Genitourin Cancer. 2023 Jun;21(3):403-414.e5. doi: 10.1016/j.clgc.2023.02.009. Epub 2023 Mar 17.
5
Plasma progastrin-releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis-targeted agents in patients with metastatic castration-resistant prostate cancer.血浆胃泌素释放肽前体水平在转移性去势抵抗性前列腺癌患者中,针对雄激素受体轴靶向药物的治疗反应具有不同的预测特征。
Cancer Rep (Hoboken). 2023 Mar;6(3):e1762. doi: 10.1002/cnr2.1762. Epub 2022 Dec 5.
6
Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.在前列腺癌细胞系中,获得性对辐射或多西紫杉醇的耐药性与顺铂的交叉耐药性无关。
J Cancer Res Clin Oncol. 2022 Jun;148(6):1313-1324. doi: 10.1007/s00432-022-03914-5. Epub 2022 Jan 12.
7
Lineage plasticity in cancer: a shared pathway of therapeutic resistance.癌症中的谱系可塑性:治疗抵抗的共同途径。
Nat Rev Clin Oncol. 2020 Jun;17(6):360-371. doi: 10.1038/s41571-020-0340-z. Epub 2020 Mar 9.
8
Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers.肿瘤抑制因子在去势抵抗性前列腺癌及侵袭性变异型神经内分泌前列腺癌的腔上皮可塑性中的作用
Front Oncol. 2018 Mar 15;8:69. doi: 10.3389/fonc.2018.00069. eCollection 2018.
9
FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.FOXA2 是前列腺小细胞神经内分泌癌的敏感且特异的标志物。
Mod Pathol. 2017 Sep;30(9):1262-1272. doi: 10.1038/modpathol.2017.44. Epub 2017 Jun 16.
10
Distinct genetic alterations in small cell carcinoma from different anatomic sites.不同解剖部位小细胞癌的独特基因改变。
Exp Hematol Oncol. 2015 Jan 14;4:2. doi: 10.1186/2162-3619-4-2. eCollection 2015.